BioCatalyst

ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®) — catalyst calendar

1 verified catalyst event(s) referencing ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®), each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-10 (month)
in 3mo
ESTIMATED
 READOUT
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Phase 3 · AMD, nAMD
 ABBV AbbVie Inc. ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2 ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.